Abstract

ASSESSMENT OF SAFETY AND EFFICACY OF EMPAGLIFLOZIN AND LINAGLIPTIN COMBINATION IN TYPE 2 DIABETES MELLITUS PATIENTS IN RVM HOSPITAL

Dandeboina Sri Deepthi Yadav, Sivvala Ragini*, Thallapally Aravind Kumar, Dr. Ithi Harika

.

Abstract

Background: Diabetes mellitus, commonly called as diabetes-which is a collection of disruptions of metabolism that results in high blood sugar, possibly due to a shortage of insulin production by the body or cells doesn’t react to the insulin that is generated. The hypoglycaemic drugs i.e.; Empagliflozin (SGLT2 inhibitor) and Linagliptin (DPP4 inhibitor) are commonly prescribed in the treatment of T2DM. Aims and Objectives: To assess whether combining empagliflozin and linagliptin is beneficial and safe in T2DM patients. Materials and Method: A total of fifty individuals within the peer group of twenty to eighty years have T2DM. The subjects were prescribed with drug Glyxambi (also named Empagliflozin)and tradjenta (also named linagliptin) in combination with the dose of 10/5 or 20/5 mg orally administered once every day for three months. The glucose/ sugar concentration in the blood is calculated i.e.; blood glucose levels after fast, postprandial blood glucose, and hemoglobin values. The results of the tests were documented. before administration of the medication and after administration of the medicine and once a month until three months. Results: The medication administration outcome is considerable in glycemia in the blood. It is observed statistically that the Tiptengio prescribed is efficient and secure in the management of DM patients. Conclusion: This study confirms that the linagliptin and empagliflozin combination is desirable for subjects with T2DM.

Keywords: Hypoglycaemicdrugs, Empagliflozin, Linagliptin.